Investigational drug · Phase 3
Glepaglutide
Also called: ZP1848
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Short Bowel Syndrome, Short Bowel Syndrome (SBS).
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
2 still active
All registered trials
9
Any phase or sponsor naming "Glepaglutide"
First trial start
2019
May 7, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Glepaglutide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Short Bowel Syndrome
- Short Bowel Syndrome (SBS)
Approved drugs for the same conditions: Rare and genetic disease · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Glepaglutide" as an intervention, largest first.
- Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBSPivotal-lookingCompleted
Zealand PharmaIndustry
NCT03905707 · 150 participants · Start May 7, 2019 · Primary completion Apr 30, 2026
Drug: glepaglutide · For: Short Bowel Syndrome
Sites: Washington D.C., District of Columbia; Chicago, Illinois; Rochester, Minnesota · 27 sites in all
- Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)Pivotal-lookingCompleted
Zealand PharmaIndustry
NCT03690206 · 106 participants · Start Oct 4, 2018 · Primary completion Jul 26, 2022
Drug: glepaglutide; Placebo · For: Short Bowel Syndrome
Sites: Washington D.C., District of Columbia; Chicago, Illinois; Rochester, Minnesota · 29 sites in all
- Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBSPivotal-lookingRecruiting
Zealand PharmaIndustry
NCT07197944 · 90 participants (planned) · Start Feb 11, 2026 · Primary completion Oct 23, 2028
Drug: Glepaglutide · For: Short Bowel Syndrome
Sites: Chicago, Illinois; St Louis, Missouri; Omaha, Nebraska · 33 sites in all
Zealand PharmaIndustry
NCT04318743 · 85 participants · Start Mar 4, 2020 · Primary completion Jun 10, 2021
Drug: Glepaglutide · For: Healthy
Sites: Groningen, Netherlands
- Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension TrialPivotal-lookingCompleted
Zealand PharmaIndustry
NCT04881825 · 84 participants · Start Jun 16, 2021 · Primary completion Apr 30, 2026
Drug: Glepaglutide · For: Short Bowel Syndrome
Sites: Washington D.C., District of Columbia; Rochester, Minnesota; Omaha, Nebraska · 19 sites in all
Zealand PharmaIndustry
NCT03279302 · 75 participants · Start Sep 4, 2017 · Primary completion Dec 18, 2017
Drug: Glepaglutide · For: Healthy Subjects
Sites: Dallas, Texas
- Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel SyndromePivotal-lookingActive, not recruiting
Zealand PharmaIndustry
NCT07228403 · 28 participants · Start Dec 11, 2025 · Primary completion Sep 18, 2028
Drug: Glepaglutide 10 mg · For: Short Bowel Syndrome (SBS)
Sites: Rochester, Minnesota; Omaha, Nebraska; Cleveland, Ohio · 16 sites in all
Zealand PharmaIndustry
NCT04178447 · 16 participants · Start Dec 10, 2019 · Primary completion Jul 14, 2020
Drug: Glepaglutide · For: Renal Impairment
Sites: Budapest, Hungary; Krakow, Poland · 3 sites in all
- The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel SyndromePivotal-lookingCompleted
Zealand PharmaIndustry
NCT04991311 · 12 participants · Start Aug 10, 2021 · Primary completion Feb 2, 2023
Drug: Glepaglutide · For: Short Bowel Syndrome
Sites: Copenhagen, Denmark
Newest research
PubMed records naming it or its code names, newest first.
- Sodium depletion is associated with the response to glepaglutide in short bowel syndrome with chronic intestinal failure.
Foerster RH, Nielsen TSS, Gallo Santacruz B, et al. · Clin Nutr ESPEN 2026
- Comment on "outcomes of glepaglutide on intestinal absorption and parenteral support in patients with short bowel syndrome".
Khatal S, Manjula, Shinde A, et al. · Clin Nutr ESPEN 2026
- Exploring the disease burden and quality of life in patients with short bowel syndrome with intestinal failure: Insights from exit interviews in the glepaglutide EASE SBS-1 phase 3 trial.
Mercer DF, Mubekapi-Musadaidzwa C, Kloster B, et al. · Nutr Clin Pract 2026
- Beyond intestinal failure: Expanding therapeutic frontiers of glucagon-like peptide-2 in gastrointestinal disease.
Attieh P, Dabboussi D, Meraabi W, et al. · World J Gastrointest Pharmacol Ther 2026
- Investigation of the stool microbiome of short bowel syndrome patients before and after a 24-week treatment with the glucagon-like peptide 2 analog glepaglutide.
Pinar I, Nielsen TSS, Brach T, et al. · Clin Nutr ESPEN 2026
- Glucagon-like peptide agonists and use in short bowel syndrome - what about the side effects?
Gorard L, Boucher M, Rutter C · Curr Opin Gastroenterol 2026
Also in development for Short Bowel Syndrome
- ApraglutidePhase 32 trials
VectivBio AG · Short Bowel Syndrome (SBS), SBS Associated With Intestinal Failure (SBS-IF), Short Bowel Syndrome
- Crofelemer forPhase 32 trials
Napo Pharmaceuticals, Inc. · Microvillus Inclusion Disease, Congenital Disorders, Rare Diseases
- PJ009Phase 31 trial
Chongqing Peg-Bio Biopharm Co., Ltd. · Short Bowel Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.